Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Future Med Chem. 2013 Jul;5(11):10.4155/fmc.13.89. doi: 10.4155/fmc.13.89

Figure 2. Ten US FDA-approved HIV-1 protease inhibitors with the year of initial FDA approval in parentheses.

Figure 2

Fosamprenavir is a prodrug of amprenavir; production of amprenavir was discontinued by the manufacturer in 2004. Tipranavir is a non-peptidomemetic inhibitor while the others are peptidomemtic inhibitors.